23
Pharma & HealthcareAvoid
Quant Healthcare
Quant · Direct–Growth · rank #18 of 19 by Smart Score
Data updated
Trailing returns
1 Year
18.1%
+20.2% vs index
3 Years
20.9%
+11.1% vs index
5 Years
—
Since launch
23.1%
Year-by-year performance
2024
+31.9%+16.2% vs index
2025
-3.6%-11.3% vs index
2026
+24.1%+27.8% vs index
Why this score
Quant Healthcare scores 23/100 — #18 of 19 Pharma & Healthcare fund (Avoid). The main drag is its volatility (better than only 3% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
Volatility18.18 · 3rd percentile in category
Expense ratio1.49% · 8th percentile in category
3Y return20.89% · 32nd percentile in category
Sharpe ratio0.92 · 22nd percentile in category
Alpha2.76 · 9th percentile in category
Sortino ratio1.15 · 23rd percentile in category
Top holdings
1.Glaxosmithkline Pharmaceuticals Ltd10.58%
2.GLENMARK PHARMACEUTICALS LTD-29-Sep-20269.83%
3.Divi's Laboratories Ltd. 29.09.20269.46%
4.Zydus Lifesciences Ltd9.3%
5.Pfizer Ltd8.83%
15 disclosed equity positions · portfolio as of Aug 2026 · weights are % of total corpus.